103 related articles for article (PubMed ID: 25071113)
1. Targeted therapy in older patients with solid tumors.
Kelly CM; Power DG; Lichtman SM
J Clin Oncol; 2014 Aug; 32(24):2635-46. PubMed ID: 25071113
[TBL] [Abstract][Full Text] [Related]
2. Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway.
Polivka J; Janku F
Pharmacol Ther; 2014 May; 142(2):164-75. PubMed ID: 24333502
[TBL] [Abstract][Full Text] [Related]
3. Beyond the vascular endothelial growth factor axis: update on role of imaging in nonantiangiogenic molecular targeted therapies in oncology.
Howard SA; Rosenthal MH; Jagannathan JP; Krajewski KM; Shinagare AB; Ramaiya NH; Tirumani SH
AJR Am J Roentgenol; 2015 May; 204(5):919-32. PubMed ID: 25905926
[TBL] [Abstract][Full Text] [Related]
4. Recent progress in the identification of BRAF inhibitors as anti-cancer agents.
El-Nassan HB
Eur J Med Chem; 2014 Jan; 72():170-205. PubMed ID: 24424304
[TBL] [Abstract][Full Text] [Related]
5. Targeted therapy and elderly people: A review.
Daste A; Chakiba C; Domblides C; Gross-Goupil M; Quivy A; Ravaud A; Soubeyran P
Eur J Cancer; 2016 Dec; 69():199-215. PubMed ID: 27855351
[TBL] [Abstract][Full Text] [Related]
6. BRAF inhibitors in cancer therapy.
Hertzman Johansson C; Egyhazi Brage S
Pharmacol Ther; 2014 May; 142(2):176-82. PubMed ID: 24325952
[TBL] [Abstract][Full Text] [Related]
7. Renal effects of molecular targeted therapies in oncology: a review by the Cancer and the Kidney International Network (C-KIN).
Launay-Vacher V; Aapro M; De Castro G; Cohen E; Deray G; Dooley M; Humphreys B; Lichtman S; Rey J; Scotté F; Wildiers H; Sprangers B
Ann Oncol; 2015 Aug; 26(8):1677-84. PubMed ID: 25735315
[TBL] [Abstract][Full Text] [Related]
8. Preclinical rationale for PI3K/Akt/mTOR pathway inhibitors as therapy for epidermal growth factor receptor inhibitor-resistant non-small-cell lung cancer.
Gadgeel SM; Wozniak A
Clin Lung Cancer; 2013 Jul; 14(4):322-32. PubMed ID: 23332287
[TBL] [Abstract][Full Text] [Related]
9. Novel chemotherapeutic approaches in adult high-grade gliomas.
Jordan JT; Wen PY
Cancer Treat Res; 2015; 163():117-42. PubMed ID: 25468229
[TBL] [Abstract][Full Text] [Related]
10. Towards personalized therapy for patients with malignant melanoma: molecular insights into the biology of BRAF mutations.
Bradish JR; Montironi R; Lopez-Beltran A; Post KM; MacLennan GT; Cheng L
Future Oncol; 2013 Feb; 9(2):245-53. PubMed ID: 23414474
[TBL] [Abstract][Full Text] [Related]
11. BRAF inhibitors: From the laboratory to clinical trials.
Rahman MA; Salajegheh A; Smith RA; Lam AK
Crit Rev Oncol Hematol; 2014 Jun; 90(3):220-32. PubMed ID: 24388103
[TBL] [Abstract][Full Text] [Related]
12. Expression of therapeutic targets in Ewing sarcoma family tumors.
Ahmed AA; Sherman AK; Pawel BR
Hum Pathol; 2012 Jul; 43(7):1077-83. PubMed ID: 22196127
[TBL] [Abstract][Full Text] [Related]
13. Anti-vascular endothelial growth factor therapy in the era of personalized medicine.
Féliz LR; Tsimberidou AM
Cancer Chemother Pharmacol; 2013 Jul; 72(1):1-12. PubMed ID: 23463481
[TBL] [Abstract][Full Text] [Related]
14. Role and therapeutic potential of PI3K-mTOR signaling in de novo resistance to BRAF inhibition.
Deng W; Gopal YN; Scott A; Chen G; Woodman SE; Davies MA
Pigment Cell Melanoma Res; 2012 Mar; 25(2):248-58. PubMed ID: 22171948
[TBL] [Abstract][Full Text] [Related]
15. Molecular targeted therapies for solid tumors: management of side effects.
Grünwald V; Soltau J; Ivanyi P; Rentschler J; Reuter C; Drevs J
Onkologie; 2009 Mar; 32(3):129-38. PubMed ID: 19295254
[TBL] [Abstract][Full Text] [Related]
16. Array-based pharmacogenomics of molecular-targeted therapies in oncology.
Sanoudou D; Mountzios G; Arvanitis DA; Pectasides D
Pharmacogenomics J; 2012 Jun; 12(3):185-96. PubMed ID: 22249357
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomas.
Migliardi G; Sassi F; Torti D; Galimi F; Zanella ER; Buscarino M; Ribero D; Muratore A; Massucco P; Pisacane A; Risio M; Capussotti L; Marsoni S; Di Nicolantonio F; Bardelli A; Comoglio PM; Trusolino L; Bertotti A
Clin Cancer Res; 2012 May; 18(9):2515-25. PubMed ID: 22392911
[TBL] [Abstract][Full Text] [Related]
18. Hotspot oncomutations: implications for personalized cancer treatment.
Myers MB; Wang Y; McKim KL; Parsons BL
Expert Rev Mol Diagn; 2012 Jul; 12(6):603-20. PubMed ID: 22845481
[TBL] [Abstract][Full Text] [Related]
19. [mTOR inhibitor].
Muro K
Gan To Kagaku Ryoho; 2011 Jan; 38(1):7-11. PubMed ID: 21368454
[TBL] [Abstract][Full Text] [Related]
20. Mutation and location important in cancer treatment.
Lewis R
Lancet Oncol; 2015 Oct; 16(13):e482. PubMed ID: 26321213
[No Abstract] [Full Text] [Related]
[Next] [New Search]
